Stock Movers Novo Nordisk Soars, Johnson & Johnson Drops, ServiceNow Falls
Dec 23, 2025
Novo Nordisk celebrates after receiving US approval for a pill version of their obesity drug Wegovy, promising significant weight loss results. Meanwhile, Johnson & Johnson faces a staggering $1.56 billion verdict over its talc baby powder's alleged cancer links. In a bold move, ServiceNow announces a $7.75 billion acquisition of cybersecurity startup Armis, though its shares take a hit in response. Tune in for insights on these major market shifts!
AI Snips
Chapters
Transcript
Episode notes
Oral Wegovy Gives Novo A Timing Edge
- Novo Nordisk's oral Wegovy approval gives it a timing edge over Eli Lilly in obesity treatment.
- The market rewarded NVO with an intraday jump of up to 11% reflecting competitive advantage expectations.
Talc Ruling Highlights Litigation Risk For J&J
- A jury ordered Johnson & Johnson to pay about $1.56 billion over talc-linked asbestos claims.
- JNJ shares slipped modestly as the ruling reinforced litigation risk tied to legacy talc products.
ServiceNow Makes Its Biggest Acquisition
- ServiceNow's $7.75 billion cash-and-debt deal for Armis is its largest acquisition to date.
- Investors sold shares, pushing NOW down about 2–3% on concerns around deal size and financing.